Found: 8
Select item for more details and to access through your institution.
Upregulation of miR145 and miR126 in EVs from Renal Cells Undergoing EMT and Urine of Diabetic Nephropathy Patients.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 20, p. 12098, doi. 10.3390/ijms232012098
- By:
- Publication type:
- Article
An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6255, doi. 10.3390/cancers14246255
- By:
- Publication type:
- Article
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6295, doi. 10.3390/cancers13246295
- By:
- Publication type:
- Article
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights.
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1519, doi. 10.3390/cancers12061519
- By:
- Publication type:
- Article
Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
- Published in:
- Molecules, 2022, v. 27, n. 2, p. 536, doi. 10.3390/molecules27020536
- By:
- Publication type:
- Article
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 11, p. 2893, doi. 10.3390/cells10112893
- By:
- Publication type:
- Article
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2023, v. 42, n. 1, p. 1, doi. 10.1186/s13046-023-02884-x
- By:
- Publication type:
- Article
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8- gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.844250
- By:
- Publication type:
- Article